Vaxart (VXRT) Expected to Announce Earnings on Thursday

Key Points

• Vaxart (VXRT) is expected to release its Q2 2025 earnings on August 14th, with analysts predicting an earnings loss of ($0.08) per share.
• The company reported a revenue of $20.88 million last quarter, surpassing expectations of $2.85 million, but it also showed a negative net margin of 122.63%.
• Insider Steven Lo recently acquired 100,000 shares of Vaxart, increasing his ownership, and institutional investors have raised their positions in the company significantly in the first quarter.

Vaxart (NASDAQ:VXRT - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Vaxart to post earnings of ($0.08) per share for the quarter.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $20.88 million during the quarter, compared to analysts' expectations of $2.85 million. Vaxart had a negative return on equity of 91.89% and a negative net margin of 122.63%. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Trading Down 2.7%

Shares of NASDAQ VXRT traded down $0.01 during mid-day trading on Friday, hitting $0.38. The company had a trading volume of 273,111 shares, compared to its average volume of 3,151,629. The company has a market capitalization of $86.99 million, a PE ratio of -1.41 and a beta of 1.12. The firm has a 50-day simple moving average of $0.44 and a two-hundred day simple moving average of $0.48. Vaxart has a one year low of $0.26 and a one year high of $1.07.

Insider Buying and Selling

In other Vaxart news, insider Steven Lo purchased 100,000 shares of Vaxart stock in a transaction that occurred on Monday, May 19th. The stock was acquired at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the completion of the acquisition, the insider owned 100,000 shares of the company's stock, valued at approximately $49,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Vaxart

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp lifted its position in Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after acquiring an additional 478,111 shares during the last quarter. Invesco Ltd. lifted its position in Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 70,568 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Vaxart during the first quarter worth approximately $31,000. Finally, Creative Planning acquired a new stake in Vaxart during the second quarter worth approximately $33,000. Institutional investors own 18.05% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Vaxart to a "hold" rating in a report on Thursday, May 22nd.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.